Effect of XXXX on @entity2407 in @entity7087 : a double-blind trial.

@entity1 @entity1095 @entity1066 @entity2407 @entity148 @entity750 @entity272 @entity6009 @entity7087
@entity6009 was used in a randomized double-blind trial in 15 @entity1 with @entity2407 in @entity7087 ( @entity7087 ). Its effect on @entity2407 was evaluated by IR-radiometry, Doppler ultrasound, nailfold capillaroscopy, frequency of finger @entity1066 and @entity1 complaints before and after a 3-month course of treatment with oral @entity6009 in the dosage of 60 mg daily in the first month and 120 mg in the second and third months. Of the 8 @entity1 treated with @entity6009 , 5 showed improvement. In the other 2 @entity1 with progression of @entity272 and multiorgan involvement, the @entity1095 was unchanged. @entity6009 treatment was discontinued in one @entity1 owing to dizziness and @entity148 . In one @entity1 @entity6009 was reduced to 60 mg daily because of fluid retention. There were no other adverse effects. In 7 control @entity1 on placebo there was no significant improvement in @entity2407 . @entity6009 , a selective, specific and pure antagonist of @entity750 ( @entity750 ) appears to be an effective agent in the treatment of @entity2407 in @entity7087 . Moreover, @entity6009 could contribute to the understanding of the role of @entity750 in @entity7087 pathogenesis.
